Ireland
--:--IST
Priya Life Science Medicines register
Registers› Irish medicines ›DOCETAXEL KABI 80 mg/4 ml concentrate for solution for infusion
Medicines register · Ireland

DOCETAXEL KABI 80 mg/4 ml concentrate for solution for infusion

Authorisation EU/1/12/770/001 · Fresenius Kabi Deutschland GmbH

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 21 Nov 2026
Licence holder
Fresenius Kabi Deutschland GmbH (all products →)
Active substance
Docetaxel
Clinical trials
275 clinical trials →
Dosage form
Concentrate for solution for infusion
Route of administration
Intravenous use
ATC codes
L01CD, L01CD02
First authorised
22/05/2012
Prescription status
Product subject to prescription which may not be renewed (A)
Supply
Supply through pharmacies only
Legal basis
Generic application (Article 10(1) of Directive No 2001/83/EC)

Docetaxel: supply and approvals

12 authorised products on the HPRA list contain Docetaxel. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
Taxotere: Shortage resolved, first published 19 May 2016
US shortage (FDA)
Docetaxel Injection: resolved, updated 20 Feb 2026
Germany (BfArM)
No entry in the BfArM supply notices (checked 20 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

Centralised EU authorisation. This product holds an EU-wide marketing authorisation granted by the European Commission after assessment by the European Medicines Agency, valid in every EU country. Its EU product number is 770. It has been authorised for 14 years (since 22 May 2012). The HPRA list does not say whether it is on sale.

Open the European Commission’s Union Register record →

Other medicines with Docetaxel in Ireland

6 other products on the HPRA list contain Docetaxel, from 2 licence holders; 0 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
DOCETAXEL KABI 120 mg/6 ml concentrate for solution for infusionFresenius Kabi Deutschland GmbHCentralised EU authorisationNot stated
DOCETAXEL KABI 160 mg/8 ml concentrate for solution for infusionFresenius Kabi Deutschland GmbHCentralised EU authorisationNot stated
DOCETAXEL KABI 180 mg/9 ml concentrate for solution for infusionFresenius Kabi Deutschland GmbHCentralised EU authorisationNot stated
Docetaxel Accord 160 mg/8 ml concentrate for solution for infusionAccord Healthcare S.L.U.Centralised EU authorisationNot stated
Docetaxel Accord 20 mg/1 ml concentrate for solution for infusionAccord Healthcare S.L.U.Centralised EU authorisationNot stated
Docetaxel Accord 80 mg/4 ml concentrate for solution for infusionAccord Healthcare S.L.U.Centralised EU authorisationNot stated

Other substances in ATC group L01CD

The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 5 other active substances share the group L01CD with this product:

Paclitaxel (4) · Docetaxel trihydrate (4) · Docetaxel (anhydrous) (1) · Anhydrous docetaxel (1) · Cabazitaxel (1)

Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.

The licence holder

Fresenius Kabi Deutschland GmbH holds 164 products on the HPRA list, with 164 different active substances; 69 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 21 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.